MedTrace Logo

Renal Effects of an Angiotensin Converting Enzyme Inhibitor in Adults With Chronic Kidney Disease of Uncertain Aetiology

NCT01624064 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2012-06-20

No results posted yet for this study

Summary

Enalapril would significantly reduce progression of renal disease in patients with Chronic Kidney Disease of Uncertain aetiology.

Conditions

  • Renal Insufficiency, Chronic

Interventions

DRUG

Enalapril

2.5-20 mg/day

DRUG

Calcium Supplement

Calcium 2.5-20 mg/day

Sponsors & Collaborators

Principal Investigators

  • Selvarajah Mathu, MBBS, MD · Ministry of Health

  • Shanthi Mendis, MBBS, MD · World Health Organization

  • Rezvi Sheriff, MBBS, MD · University of Colombo

  • Thilak Abeysekera, MBBS, MD · Ministry of Health

  • Saroj Jayasinghe, MBBS, MD · University of Colombo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2012-10-31
Completion
2013-10-31

Countries

  • Sri Lanka

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01624064 on ClinicalTrials.gov